Cargando…

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report

BACKGROUND: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Yuan, Guan, Ping, Li, Dan, Tan, Longjing, Pang, Haowen, Wen, Qinglian, Chen, Ping, Zhang, Zhenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797826/ https://www.ncbi.nlm.nih.gov/pubmed/36591480 http://dx.doi.org/10.3389/fonc.2022.1071383

Ejemplares similares

Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics
por: Zhang, Zhenhua, et al.
Publicado: (2022)

Editorial: Principles and Clinical Applications of Interstitial Brachytherapy
por: Vrachimis, Alexis
Publicado: (2022)

Dosimetric analysis of rib interference of the CTV during interstitial brachytherapy of lung tumors
por: Yang, Bo, et al.
Publicado: (2017)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target
por: Feng, Xiaojie, et al.
Publicado: (2019)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
por: Li, Yuan, et al.
Publicado: (2023)

Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience
por: Ren, Xiaojun, et al.
Publicado: (2022)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer
por: Zhou, Ping, et al.
Publicado: (2021)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer
por: Itami, Jun, et al.
Publicado: (2022)

High-Dose Rate Salvage Interstitial Brachytherapy: A Case-Based Guide to the Treatment of Therapeutically Challenging Recurrent Vulvar Cancer
por: Hughes, Kelly Eileen, et al.
Publicado: (2017)

Permanent Interstitial Cesium-131 Brachytherapy in Treating High-Risk Recurrent Head and Neck Cancer: A Prospective Pilot Study
por: Kharouta, Michael, et al.
Publicado: (2021)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Dosimetric parameters and safety analysis of 3D-printing non-coplanar template-assisted interstitial brachytherapy for non-centrally recurrent cervical cancer
por: Wang, Cong, et al.
Publicado: (2023)

Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer
por: Breen, William, et al.
Publicado: (2018)

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
por: Qian, Bing, et al.
Publicado: (2022)

Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors
por: Karagiannis, Efstratios, et al.
Publicado: (2022)

A Gene Prognostic Index Associated With Epithelial-Mesenchymal Transition Predicting Biochemical Recurrence and Tumor Chemoresistance for Prostate Cancer
por: Feng, Dechao, et al.
Publicado: (2022)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Intracavitary/Interstitial Applicator Plus Distal Parametrial Free Needle Interstitial Brachytherapy in Locally Advanced Cervical Cancer: A Dosimetric Study
por: Qu, Hong-Da, et al.
Publicado: (2021)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

High-dose-rate interstitial brachytherapy for gynecologic malignancies—dosimetric changes during treatment period
por: Onoe, Tsuyoshi, et al.
Publicado: (2013)

Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature
por: Zhang, Zhenhua, et al.
Publicado: (2022)

Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses
por: Zhang, Zhengmao, et al.
Publicado: (2019)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer
por: Chatzikonstantinou, Georgios, et al.
Publicado: (2021)

Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers
por: Zhang, Danye, et al.
Publicado: (2013)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Jiang, Qin, et al.
Publicado: (2021)

CT-guided (125)I interstitial brachytherapy for pelvic recurrent cervical carcinoma after radiotherapy
por: Tong, Lina, et al.
Publicado: (2017)

CT-guided (125)I brachytherapy for recurrent ovarian cancer
por: Liu, Ping, et al.
Publicado: (2017)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of Skull Base
por: Savard, Corey, et al.
Publicado: (2019)

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer
por: Li, Yike, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qu6f8gi6pp52tjv31j8jdd8t6c